Long-Term Outcomes of EBRT and Androgen Deprivation in Prostate Cancer Improving Clinical Trials Through Inclusion, Access, and Engagement What's Next for Frontline Metastatic RCC Therapy Addressing Underrepresentation in Oncology Clinical Trials: Barriers and Solutions ...
All men were enrolled prior to treatment and followed prospectively using the validated Prostate Cancer Symptom Indices (PCSI) instrument. This analysis compares the sexual dysfunction scores of the PCSI among patients who received external-beam RT (EBRT), EBRT with androgen deprivation therapy (ADT)...
Assessing the Need for Extended Monitoring After Axi-Cel Infusion Considering Elacestrant in ESR1+ Breast Cancer After CDK4/6 Inhibition Lenvatinib Plus Pembrolizumab Reinforces Long-Term Efficacy in Advanced RCC Long-Term Outcomes of EBRT and Androgen Deprivation in Prostate Cancer ...
The tumor size, grade, and histological subtype were found to be significant predictors for distant metastasis.Recent Videos Lenvatinib Plus Pembrolizumab Reinforces Long-Term Efficacy in Advanced RCC Long-Term Outcomes of EBRT and Androgen Deprivation in Prostate Cancer Hijioka Discusses S...
Assessing the Need for Extended Monitoring After Axi-Cel Infusion Lenvatinib Plus Pembrolizumab Reinforces Long-Term Efficacy in Advanced RCC Long-Term Outcomes of EBRT and Androgen Deprivation in Prostate Cancer Hijioka Discusses STARTER-NET: Everolimus Plus Lanreotide in GEP-NETs Exploring Zol...